Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best oversold NASDAQ stocks to buy now. On July 11, BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE), raising the price target to $115 from $100.
A biotechnologist in a white lab coat manipulating genes in a laboratory.
The analyst told investors in a research note that the new EASI-75 watermark for Biologics in Atopic Dermatitis surpassed expectations, supporting a market-leading profile and painting a positive picture for the company.
Apogee Therapeutics Inc. (NASDAQ:APGE) has $681.4 million in cash, cash equivalents, and marketable securities as of March 31. Based on the company’s current operating plans, management expects its existing cash, cash equivalents and marketable securities to support its operating expenses into the first quarter of 2028.
Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications.
While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
